

# Joost C M Meijers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4406003/publications.pdf>

Version: 2024-02-01

342  
papers

15,234  
citations

15504

65  
h-index

27406

106  
g-index

349  
all docs

349  
docs citations

349  
times ranked

16123  
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. <i>Thrombosis and Haemostasis</i> , 2022, 122, 080-091.	3.4	3
2	Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 328-338.	3.8	4
3	Coagulation in gout: is there a link with disease activity?. <i>Clinical Rheumatology</i> , 2022, 41, 1809-1815.	2.2	1
4	VhH anti- $\epsilon$ -thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1213-1222.	3.8	2
5	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1496-1506.	3.8	5
6	A FRET-based assay for the quantitation of the thrombin-factor XI interaction. <i>Thrombosis Research</i> , 2022, 214, 23-28.	1.7	3
7	Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12699.	2.3	4
8	Anti- $\epsilon$ -2 $\alpha$ -glycoprotein I and anti- $\epsilon$ -prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1018-1028.	3.8	22
9	Structure-function of anticoagulant TIX $\epsilon$ 5, the inhibitor of factor Xa-mediated FV activation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1697-1708.	3.8	1
10	Induced normothermia ameliorates the procoagulant host response in human endotoxaemia. <i>British Journal of Anaesthesia</i> , 2021, 126, 1111-1118.	3.4	3
11	Iron-Driven Alterations on Red Blood Cell-Derived Microvesicles Amplify Coagulation during Hemolysis via the Intrinsic Tenase Complex. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	3
12	Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor. <i>TH Open</i> , 2021, 05, e363-e375.	1.4	2
13	Transient ST-elevation myocardial infarction versus persistent ST-elevation myocardial infarction. An appraisal of patient characteristics and functional outcome. <i>International Journal of Cardiology</i> , 2021, 336, 22-28.	1.7	4
14	Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFP1 $\pm$ . <i>Thrombosis and Haemostasis</i> , 2020, 120, 055-064.	3.4	4
15	Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage. <i>Translational Stroke Research</i> , 2020, 11, 678-688.	4.2	24
16	Linkage analysis combined with whole-exome sequencing identifies a novel prothrombin ( <i>F2</i> ) gene mutation in a Dutch Caucasian family with unexplained thrombosis. <i>Haematologica</i> , 2020, 105, e370-e372.	3.5	6
17	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2020, 383, 1242-1247.	27.0	28
18	MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. <i>Open Heart</i> , 2020, 7, e001223.	2.3	45

#	ARTICLE	IF	CITATIONS
19	Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. <i>Neurology</i> , 2020, 95, e898-e909.	1.1	18
20	Nomenclature of factor XI and the contact system. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2216-2219.	3.8	11
21	Coagulation Factor XIII in Cerebral Venous Thrombosis. <i>TH Open</i> , 2019, 03, e227-e229.	1.4	3
22	Hydrogenâ€deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2047-2055.	3.8	16
23	In vitro evaluation of factor IX as novel treatment for factor XI deficiency. <i>Blood</i> , 2019, 134, 573-575.	1.4	7
24	Zika Virus Infection Induces Elevation of Tissue Factor Production and Apoptosis on Human Umbilical Vein Endothelial Cells. <i>Frontiers in Microbiology</i> , 2019, 10, 817.	3.5	22
25	Design and characterization of Î±1-antitrypsin variants for treatment of contact systemâ€driven thromboinflammation. <i>Blood</i> , 2019, 134, 1658-1669.	1.4	20
26	An anticoagulant that does not cause bleeding â€“ an abrupt stop on the road to the Holy Grail. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2019-2021.	3.8	2
27	Albumin plasma exchange for life-threatening angioedema with normal C1-inhibitor. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1360-1361.	3.8	2
28	Transfusion of autologous extracellular vesicles from stored red blood cells does not affect coagulation in a model of human endotoxemia. <i>Transfusion</i> , 2018, 58, 1486-1493.	1.6	7
29	Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI. <i>Thrombosis and Haemostasis</i> , 2018, 118, 340-350.	3.4	8
30	Prochemerin processing by factor XIa. <i>Blood</i> , 2018, 131, 275-276.	1.4	0
31	Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. <i>Endocrine Connections</i> , 2018, 7, 325-333.	1.9	10
32	Coagulopathy in Zellweger spectrum disorders: a role for vitamin K. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 249-255.	3.6	7
33	Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey. <i>Transfusion</i> , 2018, 58, 3014-3026.	1.6	5
34	Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid fever. <i>Journal of Infection</i> , 2018, 77, 60-67.	3.3	9
35	Abnormal coagulation and enhanced fibrinolysis due to lysinuric protein intolerance associates with bleeds and renal impairment. <i>Haemophilia</i> , 2018, 24, e312-e321.	2.1	13
36	Factor XI promotes hemostasis in factor XI-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2044-2049.	3.8	16

#	ARTICLE	IF	CITATIONS
37	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. <i>Blood</i> , 2018, 132, 1593-1603.	1.4	31
38	Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1413-1422.	3.8	17
39	Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study. <i>Journal of Neurology</i> , 2018, 265, 1612-1617.	3.6	15
40	Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay. <i>Thrombosis Research</i> , 2018, 170, 97-101.	1.7	34
41	Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia-derived sepsis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L799-L809.	2.9	16
42	Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw532.	4.0	19
43	Circulating activated protein C in thrombophilia carriers. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 361-364.	2.1	1
44	High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis. <i>Atherosclerosis</i> , 2017, 263, 377-384.	0.8	33
45	Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1392-1402.	3.8	20
46	Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. <i>Thrombosis Research</i> , 2017, 154, 1-6.	1.7	10
47	Contact ignition by single-chain XIIa. <i>Blood</i> , 2017, 129, 1411-1412.	1.4	1
48	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2017, 159, 96-99.	1.7	11
49	Factor V Leiden is associated with increased sperm count. <i>Human Reproduction</i> , 2017, 32, 2332-2339.	0.9	2
50	Novel targets for anticoagulants lacking bleeding risk. <i>Current Opinion in Hematology</i> , 2017, 24, 419-426.	2.5	17
51	Increased Circulating and Urinary Levels of Soluble TAM Receptors in Diabetic Nephropathy. <i>American Journal of Pathology</i> , 2017, 187, 1971-1983.	3.8	16
52	Editorial: Introduction to the Presentations at the Factor XI and the Contact System SSC Session of the ISTH, Montpellier, France, May 27, 2016. <i>Frontiers in Medicine</i> , 2017, 4, 140.	2.6	0
53	Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism. <i>PLoS ONE</i> , 2017, 12, e0187699.	2.5	14
54	Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1601-1614.	3.4	40

#	ARTICLE	IF	CITATIONS
55	Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005468.	3.0	7
56	Activated protein C protects against renal ischaemia/reperfusion injury, independent of its anticoagulant properties. Thrombosis and Haemostasis, 2016, 116, 124-133.	3.4	9
57	Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2016, 14, 633-644.	3.8	46
58	Impact of HIV infection on the haemostatic response during sepsis and malaria. British Journal of Haematology, 2016, 173, 918-926.	2.5	8
59	Loss of asthma control and activation of coagulation and fibrinolysis. Clinical and Experimental Allergy, 2016, 46, 422-427.	2.9	8
60	In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. British Journal of Haematology, 2016, 172, 255-261.	2.5	48
61	The influence of corticosteroids on hemostasis in healthy subjects. Journal of Thrombosis and Haemostasis, 2016, 14, 716-723.	3.8	45
62	Prothrombotic state in patients with severe and prednisolone-dependent asthma. Journal of Allergy and Clinical Immunology, 2016, 137, 1727-1732.	2.9	36
63	PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research, 2016, 140, S186-S187.	1.7	2
64	Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules. Thrombosis Research, 2016, 146, 7-14.	1.7	6
65	Use of an absorbable embolization material for reversible portal vein embolization in an experimental model. British Journal of Surgery, 2016, 103, 1306-1315.	0.3	9
66	The role of ADAMTS13 in acute myocardial infarction: cause or consequence?. Cardiovascular Research, 2016, 111, 194-203.	3.8	24
67	Kinetics of coagulation in ST-elevation myocardial infarction following successful primary percutaneous coronary intervention. Thrombosis Research, 2016, 137, 64-71.	1.7	8
68	The hypercoagulable state in hyperthyroidism is mediated via the thyroid hormone $\beta$ 2 receptor pathway. European Journal of Endocrinology, 2016, 174, 755-762.	3.7	21
69	Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation. Thrombosis Research, 2016, 139, 102-110.	1.7	7
70	A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thrombosis Research, 2016, 140, 36-40.	1.7	9
71	Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. International Journal of Cardiology, 2016, 203, 262-263.	1.7	32
72	Coagulation activation during air travel is not initiated via the extrinsic pathway. British Journal of Haematology, 2015, 169, 903-905.	2.5	4

#	ARTICLE	IF	CITATIONS
73	New clues regarding the mysterious mechanism of activated thrombin-activatable fibrinolysis inhibitor self-destruction. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1081-1083.	3.8	3
74	Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 989-997.	3.8	58
75	No association between <i>rs11209026</i> genetic variants and deep venous thrombosis. <i>British Journal of Haematology</i> , 2015, 169, 301-304.	2.5	4
76	A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. <i>Blood</i> , 2015, 125, 1822-1825.	1.4	58
77	Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin $\alpha$ -chain crosslinking. <i>Blood</i> , 2015, 126, 1940-1948.	1.4	121
78	The plasma levels of protein Z-dependent protease inhibitor increase after gynecological surgery independently of estrogen. <i>Thrombosis Research</i> , 2015, 136, 980-986.	1.7	5
79	Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1320-1324.	3.8	4
80	In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1799-1805.	3.8	66
81	Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2076-2086.	3.8	12
82	Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 920-932.	3.4	10
83	Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2093-2101.	3.8	4
84	Active but inoperable thrombin is accumulated in a plasma protein layer surrounding <i>Streptococcus pyogenes</i> . <i>Thrombosis and Haemostasis</i> , 2015, 114, 717-726.	3.4	4
85	Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia. <i>Thrombosis and Haemostasis</i> , 2015, 114, 115-122.	3.4	5
86	Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. <i>FASEB Journal</i> , 2015, 29, 3853-3862.	0.5	70
87	Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial. <i>Critical Care</i> , 2015, 19, 163.	5.8	71
88	Lowering blood glucose during hip surgery does not influence coagulation activation. <i>BBA Clinical</i> , 2015, 3, 227-232.	4.1	6
89	Hemostasis and Fibrinolysis in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 724-733.	4.3	55
90	The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis. <i>Thrombosis Research</i> , 2015, 135, 537-543.	1.7	12

#	ARTICLE	IF	CITATIONS
91	Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity. <i>Journal of Infection</i> , 2015, 71, 437-446.	3.3	17
92	Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release. <i>Frontiers in Microbiology</i> , 2015, 6, 220.	3.5	28
93	Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13. <i>American Journal of Transplantation</i> , 2015, 15, 1958-1966.	4.7	3
94	Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. <i>Thrombosis Research</i> , 2015, 136, 445-450.	1.7	15
95	Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L768-L775.	2.9	8
96	Pulmonary tuberculosis induces a systemic hypercoagulable state. <i>Journal of Infection</i> , 2015, 70, 324-334.	3.3	48
97	Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial. <i>European Respiratory Journal</i> , 2015, 46, 1636-1644.	6.7	16
98	Development of a Hypercoagulable Status in Patients Undergoing Off-Pump Lung Transplantation despite Prolonged Conventional Coagulation Tests. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 230-233.	5.6	10
99	Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e88390.	2.5	79
100	Individual with Subclinical Atherosclerosis Have Impaired Proliferation of Blood Outgrowth Endothelial Cells, Which Can Be Restored by Statin Therapy. <i>PLoS ONE</i> , 2014, 9, e99890.	2.5	11
101	Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential. <i>Thrombosis and Haemostasis</i> , 2014, 111, 458-464.	3.4	6
102	The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 970-980.	3.4	9
103	Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia. <i>BMC Infectious Diseases</i> , 2014, 14, 559.	2.9	9
104	Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 943-947.	3.8	27
105	Altered platelet contents in survivors of early ischemic ventricular fibrillation: Preliminary findings. <i>Platelets</i> , 2014, 25, 71-74.	2.3	0
106	Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 60-65.	2.5	39
107	Hyperferritinaemia in Dengue Virus Infected Patients Is Associated with Immune Activation and Coagulation Disturbances. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3214.	3.0	46
108	Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. <i>Critical Care</i> , 2014, 18, R30.	5.8	185

#	ARTICLE	IF	CITATIONS
109	Mutations in <i>STAP1</i> Are Associated With Autosomal Dominant Hypercholesterolemia. <i>Circulation Research</i> , 2014, 115, 552-555.	4.5	146
110	A role for arginine <sup>12</sup> in thrombin <sup>12</sup> -thrombomodulin <sup>12</sup> -mediated activation of thrombin <sup>12</sup> -activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1717-1725.	3.8	14
111	Acquired von <i>Willebrand</i> syndrome in patients with overt hypothyroidism: a prospective cohort study. <i>Haemophilia</i> , 2014, 20, 326-332.	2.1	28
112	Factor XI Regulates Pathological Thrombus Formation on Acutely Ruptured Atherosclerotic Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1668-1673.	2.4	47
113	Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. <i>Acta Neuropathologica</i> , 2014, 127, 553-564.	7.7	17
114	Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study. <i>Respiratory Research</i> , 2014, 15, 14.	3.6	21
115	Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1674-1680.	2.4	108
116	Evaluating the Optimal Timing of Revascularisation in Patients with Transient ST-Segment Elevation Myocardial Infarction: Rationale and Design of the TRANSIENT Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 590-596.	2.4	10
117	Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. <i>BMC Microbiology</i> , 2014, 14, 134.	3.3	30
118	The influence of HIV infection on coagulation activation during sepsis. <i>International Journal of Infectious Diseases</i> , 2014, 21, 128.	3.3	0
119	Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI. <i>Thrombosis Research</i> , 2014, 133, 1166-1168.	1.7	0
120	No contact, no thrombosis?. <i>Blood</i> , 2014, 123, 1629-1629.	1.4	6
121	Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. <i>Thrombosis and Haemostasis</i> , 2014, 112, 304-310.	3.4	6
122	Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?. <i>Thrombosis and Haemostasis</i> , 2014, 112, 736-742.	3.4	26
123	C0288: Lack of TAFI Has Deleterious Effect on Experimental Ischemic Stroke: Potential Role of Microparticles. <i>Thrombosis Research</i> , 2014, 133, S5.	1.7	1
124	Treatment with everolimus is associated with a procoagulant state. <i>Thrombosis Research</i> , 2013, 132, 307-311.	1.7	42
125	Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 282-292.	3.8	20
126	Urinary prothrombin fragment 1+2 in patients with venous thrombosis and myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 47-49.	2.1	0



#	ARTICLE	IF	CITATIONS
127	The Aggregation Potential of the 1â€“15- and 1â€“16-Fragments of the Amyloid Î² Peptide and Their Influence on the Aggregation of AÎ²40. <i>Applied Magnetic Resonance</i> , 2013, 44, 1167-1179.	1.2	3
128	Circulating Nucleosomes and Neutrophil Activation as Risk Factors for Deep Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 147-151.	2.4	193
129	Endogenous Î±2-Antiplasmin Is Protective during Severe Gram-Negative Sepsis (Melioidosis). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 967-975.	5.6	33
130	Decreased tissue factor pathway inhibitor (<sc>TFPI</sc>)â€“dependent anticoagulant capacity in patients with cirrhosis who have decreased protein <sc>S</sc> but normal <sc>TFPI</sc> plasma levels. <i>British Journal of Haematology</i> , 2013, 162, 819-826.	2.5	14
131	VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 1629-1634.	8.6	40
132	Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. <i>International Journal of Cardiology</i> , 2013, 168, 472-477.	1.7	33
133	Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. <i>Thrombosis and Haemostasis</i> , 2013, 109, 214-220.	3.4	16
134	An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. <i>Hepatology</i> , 2013, 58, 752-761.	7.3	153
135	Overexpression of the Endothelial Protein C Receptor Is Detrimental during Pneumonia-Derived Gram-negative Sepsis (Melioidosis). <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2306.	3.0	14
136	The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2013, 41, 935-942.	6.7	8
137	Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System. <i>Circulation</i> , 2013, 128, 254-266.	1.6	84
138	Differential Effects of Nonselective Versus Selective Î²-Blockers on Cardiac Sympathetic Activity and Hemostasis in Patients with Heart Failure. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1733-1739.	5.0	11
139	Clot lysis phenotype and response to recombinant factor <sc>VII</sc>a in plasma of haemophilia A inhibitor patients. <i>British Journal of Haematology</i> , 2013, 162, 827-835.	2.5	10
140	Intrabronchial activated protein C enhances lipopolysaccharide-induced pulmonary responses. <i>European Respiratory Journal</i> , 2013, 42, 188-197.	6.7	10
141	Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. <i>Haemophilia</i> , 2013, 19, 744-752.	2.1	22
142	Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1787-1788.	3.8	2
143	Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1065-1073.	3.4	30
144	Differences in platelet microRNA profiles after aspirin use are associated with differences in whole blood aggregation and might identify aspirin resistance. <i>European Heart Journal</i> , 2013, 34, P4884-P4884.	2.2	0

#	ARTICLE	IF	CITATIONS
145	Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*. <i>Critical Care Medicine</i> , 2013, 41, e266-e274.	0.9	8
146	TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 948-955.	3.4	19
147	The endothelial protein C receptor and activated protein C play a limited role in host defense during experimental tuberculosis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 726-737.	3.4	7
148	Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 633-642.	3.4	33
149	Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 223-232.	3.4	33
150	Endogenous tissue-type plasminogen activator impairs host defense during severe experimental gram-negative sepsis (melioidosis)*. <i>Critical Care Medicine</i> , 2012, 40, 2168-2175.	0.9	19
151	BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. <i>Blood</i> , 2012, 119, 1440-1449.	1.4	33
152	Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1312-1319.	3.8	101
153	Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. <i>Pituitary</i> , 2012, 15, 472-481.	2.9	13
154	Recombinant C1-Inhibitor. <i>BioDrugs</i> , 2012, 26, 43-52.	4.6	28
155	Chronic pulmonary embolism in Klippel-Trenaunay syndrome. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 71-77.	1.2	31
156	Review: Viral infections and mechanisms of thrombosis and bleeding. <i>Journal of Medical Virology</i> , 2012, 84, 1680-1696.	5.0	252
157	Reply from the authors. <i>Hepatology Research</i> , 2012, 42, 1154-1155.	3.4	0
158	The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2555-2562.	3.8	22
159	Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. <i>Thrombosis Research</i> , 2012, 130, 355-360.	1.7	17
160	Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage. <i>Thrombosis and Haemostasis</i> , 2012, 107, 507-512.	3.4	5
161	Recent developments in our understanding of the antiphospholipid syndrome. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 223-231.	1.3	26
162	<i>Factor XIII Val34Leu</i> mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. <i>Hepatology Research</i> , 2012, 42, 668-676.	3.4	11

#	ARTICLE	IF	CITATIONS
163	Clinical practice. <i>European Journal of Pediatrics</i> , 2012, 171, 207-214.	2.7	21
164	Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. <i>Critical Care</i> , 2011, 15, R59.	5.8	50
165	The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, E57-E63.	1.7	23
166	Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 189-194.	1.4	18
167	Activated human platelet products induce proarrhythmic effects in ventricular myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 347-356.	1.9	5
168	Acute Stress Elicited by Bungee Jumping Suppresses Human Innate Immunity. <i>Molecular Medicine</i> , 2011, 17, 180-188.	4.4	36
169	Quantitative trait locus for protein C in a family with thrombophilia. <i>Thrombosis and Haemostasis</i> , 2011, 105, 199-201.	3.4	4
170	Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B. <i>Thrombosis and Haemostasis</i> , 2011, 106, 609-616.	3.4	6
171	Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis). <i>Thrombosis and Haemostasis</i> , 2011, 106, 1139-1148.	3.4	13
172	Evolutionary conservation of the lipopolysaccharide binding site of $\beta_2$ -glycoprotein I. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1069-1075.	3.4	34
173	Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. <i>PLoS ONE</i> , 2011, 6, e25946.	2.5	86
174	Identification and Characterization of Ixodes scapularis Antigens That Elicit Tick Immunity Using Yeast Surface Display. <i>PLoS ONE</i> , 2011, 6, e15926.	2.5	72
175	Vascular Endothelial Growth Factor in the Circulation in Cancer Patients May Not Be a Relevant Biomarker. <i>PLoS ONE</i> , 2011, 6, e19873.	2.5	43
176	Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. <i>Journal of Hypertension</i> , 2011, 29, 922-927.	0.5	48
177	The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. <i>Blood</i> , 2011, 117, 2070-2072.	1.4	22
178	$\beta_2$ -Glycoprotein I: a novel component of innate immunity. <i>Blood</i> , 2011, 117, 6939-6947.	1.4	101
179	Increased coagulation factor VIII activity in patients with familial hypercholesterolemia. <i>Blood</i> , 2011, 118, 6990-6991.	1.4	11
180	Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 953-958.	3.8	21

#	ARTICLE	IF	CITATIONS
181	High levels of protein C are determined by PROCR haplotype 3. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 969-976.	3.8	17
182	β <sub>2</sub> -Glycoprotein I: evolution, structure and function. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1275-1284.	3.8	180
183	Acute respiratory tract infection leads to procoagulant changes in human subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1432-1434.	3.8	23
184	Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1657-1659.	3.8	82
185	Influenza vaccination and hemostasis: no sustainable procoagulant effects from 2009 H1N1 influenza vaccine in healthy healthcare workers. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1659-1661.	3.8	1
186	Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1816-1824.	3.8	40
187	Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2020-2028.	3.8	34
188	Induction of anti-β <sub>2</sub> -glycoprotein I autoantibodies in mice by protein H of <i>Streptococcus pyogenes</i> . <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2447-2456.	3.8	35
189	Protein C Inhibitor. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 349-354.	2.7	34
190	Forgotten Factors in Hemostasis and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 337-338.	2.7	0
191	β <sub>2</sub> -Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. <i>Blood</i> , 2010, 116, 1336-1343.	1.4	247
192	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. <i>Blood</i> , 2010, 116, 113-121.	1.4	309
193	The effects of an extremely high dose of levothyroxine on coagulation and fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1427-1428.	3.8	13
194	Expression patterns of protein C inhibitor in mouse development. <i>Journal of Molecular Histology</i> , 2010, 41, 27-37.	2.2	7
195	Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. <i>AIDS Research and Therapy</i> , 2010, 7, 9.	1.7	40
196	Increased sperm count may account for high population frequency of factor V Leiden. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 513-516.	3.8	11
197	Explanations for coagulation activation after air travel. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 971-978.	3.8	25
198	Intact thrombomodulin-mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulin-mediated regulation of coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1646-1649.	3.8	12

#	ARTICLE	IF	CITATIONS
199	Hyperglycemia: a prothrombotic factor?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1663-1669.	3.8	227
200	Thrombin-activatable fibrinolysis inhibitor is degraded by <i>Salmonella enterica</i> and <i>Yersinia pestis</i> . <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2232-2240.	3.8	21
201	Coagulation factor XI as a novel target for antithrombotic treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2349-2357.	3.8	67
202	Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. <i>Tropical Medicine and International Health</i> , 2010, 15, 152-159.	2.3	61
203	The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1228-1234.	3.4	58
204	Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. <i>Thrombosis and Haemostasis</i> , 2010, 103, 181-187.	3.4	70
205	Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. <i>Blood</i> , 2010, 116, 4684-4692.	1.4	172
206	Urokinase Receptor Is Necessary for Bacterial Defense against Pneumonia-Derived Septic Melioidosis by Facilitating Phagocytosis. <i>Journal of Immunology</i> , 2010, 184, 3079-3086.	0.8	49
207	Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9083-9087.	7.1	30
208	Systemic Inflammatory Response Syndrome and Compensatory Anti-Inflammatory Response Syndrome in Sepsis. <i>Journal of Innate Immunity</i> , 2010, 2, 379-380.	3.8	33
209	Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. <i>Journal of Hepatology</i> , 2010, 52, 355-361.	3.7	191
210	Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. <i>Thrombosis Research</i> , 2010, 125, 97-99.	1.7	6
211	The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing. <i>Thrombosis Research</i> , 2010, 126, 442-446.	1.7	15
212	Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke. <i>PLoS ONE</i> , 2010, 5, e11658.	2.5	32
213	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-470.	3.4	30
214	The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. <i>Thrombosis and Haemostasis</i> , 2009, 102, 460-468.	3.4	8
215	The Hemostatic Balance in HIV-Infected Patients with and without Antiretroviral Therapy: Partial Restoration with Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2009, 23, 1001-1007.	2.5	47
216	Activation of TAFI on the Surface of <i>Streptococcus pyogenes</i> Evokes Inflammatory Reactions by Modulating the Kallikrein/Kinin System. <i>Journal of Innate Immunity</i> , 2009, 1, 18-28.	3.8	33

#	ARTICLE	IF	CITATIONS
217	Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. <i>Kidney International</i> , 2009, 75, 52-59.	5.2	35
218	Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1165-1173.	2.4	14
219	Protein C Inhibitor—A Novel Antimicrobial Agent. <i>PLoS Pathogens</i> , 2009, 5, e1000698.	4.7	34
220	The Receptor for Advanced Glycation End Products Impairs Host Defense in Pneumococcal Pneumonia. <i>Journal of Immunology</i> , 2009, 182, 4349-4356.	0.8	99
221	ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO. <i>Shock</i> , 2009, 31, 280-284.	2.1	237
222	Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. <i>Haematologica</i> , 2009, 94, 811-818.	3.5	42
223	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1444-1453.	4.3	118
224	Reduced ADAMTS13 Activity in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1734-1741.	4.3	42
225	ApoA1-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 347-354.	3.8	20
226	Î2-Glycoprotein I is incorrectly named apolipoprotein H. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 235-236.	3.8	54
227	The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 445-452.	3.8	20
228	Venous thrombosis is associated with hyperglycemia at diagnosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 945-949.	3.8	40
229	Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. <i>Haematologica</i> , 2009, 94, 1513-1519.	3.5	241
230	Tumor necrosis factor-Î± inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. <i>Atherosclerosis</i> , 2009, 202, 296-303.	0.8	136
231	Urokinase Plasminogen Activator Receptor-Deficient Mice Demonstrate Reduced Hyperoxia-Induced Lung Injury. <i>American Journal of Pathology</i> , 2009, 174, 2182-2189.	3.8	12
232	Feedback controversy stops here. <i>Blood</i> , 2009, 114, 235-235.	1.4	10
233	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-70.	3.4	6
234	Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 132-138.	3.8	9

#	ARTICLE	IF	CITATIONS
235	Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 32-39.	3.8	38
236	Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2168-2174.	3.8	31
237	The antibacterial activity of peptides derived from human beta $\alpha$ 2 glycoprotein I is inhibited by protein H and M1 protein from <i>Streptococcus pyogenes</i> . <i>Molecular Microbiology</i> , 2008, 67, 482-492.	2.5	32
238	Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 910-916.	2.1	55
239	Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema. <i>Clinical Therapeutics</i> , 2008, 30, 2314-2323.	2.5	46
240	Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension. <i>Hypertension</i> , 2008, 51, 862-866.	2.7	80
241	Platelet-Activating Factor Receptor Contributes to Host Defense against <i>Pseudomonas aeruginosa</i> Pneumonia but Is Not Essential for the Accompanying Inflammatory and Procoagulant Response. <i>Journal of Immunology</i> , 2008, 180, 3357-3365.	0.8	16
242	Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery. <i>British Journal of Anaesthesia</i> , 2008, 100, 442-450.	3.4	26
243	Endogenous $\beta$ -Adrenergic Receptors Inhibit Lipopolysaccharide-Induced Pulmonary Cytokine Release and Coagulation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 373-379.	2.9	13
244	Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. <i>Blood</i> , 2008, 112, 2803-2809.	1.4	69
245	Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. <i>Blood</i> , 2008, 112, 82-89.	1.4	221
246	Fluid loss does not explain coagulation activation during air travel. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1053-1059.	3.4	31
247	Circulating Erythrocyte-Derived Microparticles Are Associated with Coagulation Activation in Sickle Cell Disease. <i>Blood</i> , 2008, 112, 126-126.	1.4	7
248	Severe Malaria and Leptospirosis Are Associated with a Deficiency of the Von Willebrand Factor Cleaving Protease, ADAMTS13. <i>Blood</i> , 2008, 112, 3912-3912.	1.4	2
249	Thrombin-activatable Fibrinolysis Inhibitor Binds to <i>Streptococcus pyogenes</i> by Interacting with Collagen-like Proteins A and B. <i>Journal of Biological Chemistry</i> , 2007, 282, 24873-24881.	3.4	36
250	Prednisolone Dose-Dependently Influences Inflammation and Coagulation during Human Endotoxemia. <i>Journal of Immunology</i> , 2007, 178, 1845-1851.	0.8	94
251	Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. <i>Journal of Lipid Research</i> , 2007, 48, 952-960.	4.2	65
252	Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. <i>Critical Care</i> , 2007, 11, R102.	5.8	20

#	ARTICLE	IF	CITATIONS
253	EFFECTS OF INTRA-ABDOMINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR ON COAGULATION, FIBRINOLYSIS AND INFLAMMATORY RESPONSES IN EXPERIMENTAL POLYMICROBIAL PERITONITIS. <i>Shock</i> , 2007, 27, 534-541.	2.1	9
254	High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1153-1158.	2.4	102
255	Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2007, 1771, 1429-1438.	2.4	76
256	Tissue factor-dependent blood coagulation is enhanced following delivery irrespective of the mode of delivery. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2415-2420.	3.8	36
257	Activation of coagulation system during air travel: a crossover study. <i>Lancet, The</i> , 2006, 367, 832-838.	13.7	162
258	Tu-P10:482 Possible mechanism underlying the association between C-reactive protein and cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2006, 7, 291.	1.2	0
259	The effects of continuous venovenous hemofiltration on coagulation activation. <i>Critical Care</i> , 2006, 10, R150.	5.8	26
260	Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. <i>Blood</i> , 2006, 108, 4045-4051.	1.4	214
261	Effect of Hypobaric Hypoxia, Simulating Conditions During Long-Haul Air Travel, on Coagulation, Fibrinolysis, Platelet Function, and Endothelial Activation. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2251.	7.4	117
262	Predilution Versus Postdilution During Continuous Venovenous Hemofiltration: A Comparison of Circuit Thrombogenesis. <i>ASAIO Journal</i> , 2006, 52, 416-422.	1.6	27
263	Proteomic analysis of high-density lipoprotein. <i>Proteomics</i> , 2006, 6, 721-730.	2.2	169
264	Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 257-258.	3.8	1
265	The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1418-1420.	3.8	24
266	The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1701-1706.	3.8	12
267	Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1997-2002.	3.8	166
268	Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2343-2351.	3.8	13
269	Endotoxaemia induces resistance to activated protein C in healthy humans. <i>British Journal of Haematology</i> , 2006, 134, 213-219.	2.5	24
270	Effects on Coagulation and Fibrinolysis Induced by Influenza in Mice With a Reduced Capacity to Generate Activated Protein C and a Deficiency in Plasminogen Activator Inhibitor Type 1. <i>Circulation Research</i> , 2006, 99, 1261-1269.	4.5	77



#	ARTICLE	IF	CITATIONS
271	Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. <i>European Respiratory Journal</i> , 2006, 28, 992-998.	6.7	28
272	Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. <i>Diabetes</i> , 2006, 55, 480-486.	0.6	469
273	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. <i>Blood</i> , 2005, 105, 1102-1105.	1.4	246
274	Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1293-1300.	3.8	10
275	The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1531-1533.	3.8	17
276	Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1993-1997.	3.8	183
277	Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2123-2125.	3.8	11
278	Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. <i>Intensive Care Medicine</i> , 2005, 31, 724-732.	8.2	39
279	Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. <i>Thrombosis Journal</i> , 2005, 3, 12.	2.1	31
280	The value of haemostatic markers in the triage of patients with chest pain presenting with a normal or non-diagnostic ECG. <i>Heart</i> , 2005, 91, 1215-1216.	2.9	1
281	Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans. <i>Circulation Research</i> , 2005, 96, 714-716.	4.5	208
282	Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice. <i>Journal of Immunology</i> , 2005, 175, 6764-6771.	0.8	56
283	Lipopolysaccharide Is Transferred from High-Density to Low-Density Lipoproteins by Lipopolysaccharide-Binding Protein and Phospholipid Transfer Protein. <i>Infection and Immunity</i> , 2005, 73, 2321-2326.	2.2	129
284	Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. <i>Critical Care</i> , 2005, 9, R490.	5.8	28
285	Hypercoagulability in the metabolic syndrome. <i>Current Opinion in Pharmacology</i> , 2005, 5, 155-159.	3.5	157
286	Effects of Clopidogrel on the Rebound Hypercoagulable State After Heparin Discontinuation in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1582-1583.	2.8	17
287	Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. <i>Journal of Applied Physiology</i> , 2004, 97, 2014-2019.	2.5	33
288	Anti-Inflammatory and Anticoagulant Effects of Pravastatin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 468-473.	8.6	39

#	ARTICLE	IF	CITATIONS
289	Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor. <i>Journal of Biological Chemistry</i> , 2004, 279, 6620-6628.	3.4	21
290	Absence of mutations in the PCI gene in subfertile men. <i>Molecular Human Reproduction</i> , 2004, 10, 807-813.	2.8	10
291	Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. <i>British Journal of Haematology</i> , 2004, 124, 653-658.	2.5	99
292	Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 65-70.	3.8	36
293	Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 769-779.	3.8	19
294	Mechanism of action of carboxypeptidase U: staying above the threshold. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 414-415.	3.8	1
295	Protein C and S and inflammation in sickle cell disease. <i>American Journal of Hematology</i> , 2004, 76, 26-32.	4.1	31
296	New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). <i>Seminars in Hematology</i> , 2004, 41, 13-19.	3.4	37
297	Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation*. <i>Critical Care Medicine</i> , 2004, 32, 2416-2421.	0.9	419
298	Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. <i>Blood</i> , 2004, 103, 1702-1709.	1.4	111
299	Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. <i>Blood</i> , 2004, 103, 927-933.	1.4	135
300	Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. <i>Blood</i> , 2004, 104, 128-134.	1.4	92
301	The Role of the Fibrinolytic System in Corneal Angiogenesis. <i>Angiogenesis</i> , 2003, 6, 311-316.	7.2	15
302	Procoagulant protein levels are differentially increased during human endotoxemia. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1019-1023.	3.8	43
303	Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R,) Tj ETQq1 1 0.784314 rgBT /Ove 3.8 155	3.8	155
304	Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2087-2096.	3.8	82
305	Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2368-2373.	3.8	70
306	The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 42, 424-427.	2.8	14

#	ARTICLE	IF	CITATIONS
307	Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416. <i>Journal of Clinical Oncology</i> , 2003, 21, 2192-2198.	1.6	113
308	Effects of IC14, an Anti-CD14 Antibody, on Coagulation and Fibrinolysis during Low-Grade Endotoxemia in Humans. <i>Journal of Infectious Diseases</i> , 2003, 187, 55-61.	4.0	39
309	Distribution and Kinetics of Lipoprotein-Bound Lipoteichoic Acid. <i>Infection and Immunity</i> , 2003, 71, 3280-3284.	2.2	86
310	Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. <i>Blood</i> , 2003, 101, 4844-4846.	1.4	102
311	Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. <i>Molecular Cancer Research</i> , 2003, 1, 561-8.	3.4	30
312	Characterization of the H-kininogen-binding Site on Factor XI. <i>Journal of Biological Chemistry</i> , 2002, 277, 4892-4899.	3.4	64
313	Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1500-1505.	2.4	141
314	Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers. <i>Circulation</i> , 2002, 106, 2550-2554.	1.6	311
315	Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 373-381.	1.0	15
316	Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. <i>Blood</i> , 2002, 99, 175-179.	1.4	159
317	Effects of Second and Third Generation Oral Contraceptives and their Respective Progestagens on the Coagulation System in the Absence or Presence of the Factor V Leiden Mutation. <i>Thrombosis and Haemostasis</i> , 2002, 87, 199-205.	3.4	58
318	Plasmin-Mediated Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitor. <i>Biochemistry</i> , 2002, 41, 6688-6696.	2.5	71
319	Role of Zinc Ions in Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitor. <i>Biochemistry</i> , 2002, 41, 1211-1216.	2.5	20
320	Rebound thrombin generation after heparin therapy in unstable angina. <i>Journal of the American College of Cardiology</i> , 2002, 39, 811-817.	2.8	54
321	No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. <i>American Journal of Hematology</i> , 2002, 71, 53-55.	4.1	10
322	Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis. <i>British Journal of Haematology</i> , 2002, 118, 604-609.	2.5	15
323	Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. <i>British Journal of Haematology</i> , 2001, 113, 94-99.	2.5	38
324	Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. <i>British Journal of Haematology</i> , 2001, 113, 621-629.	2.5	66

#	ARTICLE	IF	CITATIONS
325	Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. British Journal of Haematology, 2000, 108, 518-523.	2.5	66
326	Protein C inhibitor in platelets?. Blood, 2000, 95, 1880-1881.	1.4	0
327	C4b-Binding Protein Protects Coagulation Factor Va from Inactivation by Activated Protein C. Biochemistry, 2000, 39, 14543-14548.	2.5	13
328	R-205. Protein C inhibitor/plasminogen activator inhibitor-3 is present in the mouse ovary and is down-regulated by human chorionic gonadotrophin treatment. Human Reproduction, 1999, 14, 370-371.	0.9	0
329	Binding of amyloid $\beta$ precursor protein to coagulation factor XIa in vivo may favour haemorrhagic stroke. Journal of Neurology, 1998, 245, 111-115.	3.6	6
330	Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen activator) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.1	7
331	Factor XI Activation by Meizothrombin: Stimulation by Phospholipid Vesicles Containing both Phosphatidylserine and Phosphatidylethanolamine. Thrombosis and Haemostasis, 1997, 78, 834-839.	3.4	27
332	Role of the A+ Helix in Heparin Binding to Protein C Inhibitor. Thrombosis and Haemostasis, 1996, 75, 760-766.	3.4	32
333	Effect of Heparin on the Activation of Factor XI by Fibrin-bound Thrombin. Thrombosis and Haemostasis, 1996, 76, 347-353.	3.4	15
334	The Interaction of Protein S with the Phospholipid Surface Is Essential for the Activated Protein C-independent Activity of Protein S. Thrombosis and Haemostasis, 1996, 76, 397-403.	3.4	63
335	Apple four in human blood coagulation factor XI mediates dimer formation. Biochemistry, 1992, 31, 4680-4684.	2.5	87
336	Inhibition of human blood coagulation factor XIa by C.hivin.1 inhibitor. Biochemistry, 1988, 27, 959-963.	2.5	34
337	Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry, 1988, 27, 4231-4237.	2.5	122
338	Oral contraceptives reduce total protein S, but not free protein S.. Thrombosis Research, 1987, 45, 109-114.	1.7	45
339	Inhibition of human blood coagulation factor Xa by .alpha.2-macroglobulin. Biochemistry, 1987, 26, 5932-5937.	2.5	37
340	Characterization of human protein S. Thrombosis Research, 1986, 41, 135.	1.7	1
341	Analysis of tumour-localizing haematoporphyrin derivative by high-performance liquid chromatography and fast-atom bombardment mass spectrometry. Journal of Chromatography A, 1986, 352, 231-239.	3.7	13
342	Nanobodies against factor $\text{XI}$ apple 3 domain inhibit binding of factor $\text{IX}$ and reveal a novel binding site for high molecular weight kininogen. Journal of Thrombosis and Haemostasis, 0, , .	3.8	5